Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Annals of Emergency Medicine|May 23, 2002
Delayed valproic acid toxicity: a retrospective case seriesMarianne Ingels, Jon Beauchamp, Richard F Clark, et al.Journal of Neurology|June 3, 2026
Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT)James F Howard, Francesco Saccà, Sarah Hoffmann, et al.BMJ Open|July 21, 2021
Patient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG)Sonia Berrih-Aknin, Kristl G Claeys, Nancy Law, et al.BMJ Open|May 11, 2023
Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG)Sonia Berrih-Aknin, Jacqueline Palace, Andreas Meisel, et al.Expert Review of Clinical Immunology|April 29, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseasesKelly G Gwathmey, Catherine M Broome, Matthias Goebeler, et al.BMJ Open|January 31, 2023
Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MGSarah Dewilde, Glenn Philips, Sandra Paci, et al.American Journal of Hematology|December 11, 2019
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAdrian C Newland, Blanca Sánchez-González, László Rejtő, et al.British Journal of Haematology|February 16, 2010
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumabRichard Kelly, Louise Arnold, Stephen Richards, et al.Pageof 1